Applying AI-Driven Biosimulation to Drug Discovery Video Applying AI-Driven Biosimulation to Drug Discovery Certara President Leif Pedersen explains how PBPK and QSP modeling, proven across 125+ FDA-approved drugs,…Certara2026年6月2日
Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment Publication Review: application and opportunities for machine learning and artificial intelligence in preclinical immunogenicity risk assessment This review explores how artificial intelligence (AI), machine learning (ML), and quantitative systems pharmacology (QSP)…Certara2026年6月2日
ADC dose optimization: Applying model-informed strategies in development Blog ADC dose optimization: Applying model-informed strategies in development Explore ADC dose optimization using model-informed strategies to balance efficacy and safety across antibody drug…Certara2026年4月22日
An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors Publication An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors This publication highlights how pharmacometric modeling, supported by Certara, was used to inform dose selection…Certara2026年3月25日
Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs) On-Demand Webinar Right Dose, Right Regimen: Model-Informed Strategies for Antibody–Drug Conjugates (ADCs) Watch this on-demand webinar to learn how model-informed strategies using PopPK, PBPK, and QSP can…Certara2026年3月25日
Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis Publication Model-informed drug development to support nemolizumab clinical development in adults and adolescents with moderate to severe atopic dermatitis This article describes how a model-informed drug development (MIDD) approach was used to support the…Certara2026年3月24日
ADC first-in-human (FIH) dose selection: Designing FIH studies for success Blog ADC first-in-human (FIH) dose selection: Designing FIH studies for success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…Certara2026年3月3日
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success On-Demand Webinar Start right, finish strong: Antibody-drug conjugate (ADC) studies for success Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…Certara2026年2月23日
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants Publication Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…Certara2026年2月2日
The rise of biologics discovery: From small molecules to sequences Blog The rise of biologics discovery: From small molecules to sequences Biologics in drug discovery is becoming more important by the year. See where biologics discovery…Certara2026年1月15日